NASDAQ · BCYC
Healthcare · Biotechnology
$4.37
Up+$0.13 (+3.07%)
Updated Aug 22, 2026, 6:52 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
BCYC closed at $4.37 after 21 trading sessions, up 12.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $4.29 | $4.51 | $4.252 | $4.37 | 480.75K |
| Aug 20, 2026 | $4.11 | $4.27 | $4.035 | $4.24 | 374.17K |
| Aug 19, 2026 | $4.05 | $4.16 | $4.03 | $4.14 | 346.47K |
| Aug 18, 2026 | $3.99 | $4.025 | $3.95 | $3.99 | 106.81K |
| Aug 17, 2026 | $3.88 | $4.0246 | $3.88 | $4.00 | 341.66K |
| Aug 14, 2026 | $3.95 | $3.97 | $3.87 | $3.90 | 468.12K |
| Aug 13, 2026 | $4.105 | $4.105 | $3.96 | $3.98 | 459.12K |
| Aug 12, 2026 | $4.14 | $4.15 | $4.035 | $4.06 | 639.93K |
| Aug 11, 2026 | $4.11 | $4.15 | $4.085 | $4.12 | 107.22K |
| Aug 10, 2026 | $4.20 | $4.21 | $4.065 | $4.11 | 202.53K |
| Aug 7, 2026 | $4.07 | $4.206 | $4.04 | $4.17 | 288.7K |
| Aug 6, 2026 | $3.96 | $4.03 | $3.93 | $3.97 | 225.05K |
| Aug 5, 2026 | $3.95 | $4.025 | $3.92 | $3.97 | 287.69K |
| Aug 4, 2026 | $3.90 | $3.97 | $3.875 | $3.94 | 179.67K |
| Aug 3, 2026 | $3.81 | $3.915 | $3.745 | $3.87 | 340.37K |
| Jul 31, 2026 | $4.01 | $4.01 | $3.80 | $3.86 | 336.08K |
| Jul 30, 2026 | $3.86 | $4.03 | $3.81 | $4.01 | 418.98K |
| Jul 29, 2026 | $3.93 | $4.03 | $3.85 | $3.86 | 352.22K |
| Jul 28, 2026 | $3.98 | $3.98 | $3.895 | $3.94 | 320.85K |
| Jul 27, 2026 | $3.90 | $4.02 | $3.88 | $3.95 | 303.82K |
| Jul 24, 2026 | $4.16 | $4.16 | $3.87 | $3.87 | 572.86K |
The latest Smart Investors Daily articles mentioning BCYC.
BCYC research
Company profile and research snapshot.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Needham | Buy | — |
| Apr 8, 2026 | Morgan Stanley | Equal-Weight | — |
| Mar 18, 2026 | RBC Capital | Sector Perform | — |
| Mar 18, 2026 | Citizens | Market Outperform | — |
| Mar 18, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Aug 4, 2026
Bicycle Therapeutics deprioritized zelenectide pevedotin after mixed progress in urothelial cancer. Find out why BCYC stock is downgraded to a hold.
Benzinga · Jul 30, 2026
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.
Benzinga · Jul 30, 2026
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.59) by 22.03 percent. This is a 36.84 percent increase over losses of $(1.14) per
Yahoo · Jun 2, 2026
European equities traded in the US as American depositary receipts were tracking higher late Tuesday
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCYC.
